WO1994025600A1 - Antigenes recombines du virus ourlien et leur utilisation dans les vaccins - Google Patents
Antigenes recombines du virus ourlien et leur utilisation dans les vaccins Download PDFInfo
- Publication number
- WO1994025600A1 WO1994025600A1 PCT/EP1994/001297 EP9401297W WO9425600A1 WO 1994025600 A1 WO1994025600 A1 WO 1994025600A1 EP 9401297 W EP9401297 W EP 9401297W WO 9425600 A1 WO9425600 A1 WO 9425600A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- die
- designated
- membrane anchor
- vector
- Prior art date
Links
- 241000711386 Mumps virus Species 0.000 title claims abstract description 16
- 239000000427 antigen Substances 0.000 title claims abstract description 5
- 102000036639 antigens Human genes 0.000 title claims abstract description 5
- 108091007433 antigens Proteins 0.000 title claims abstract description 5
- 229960005486 vaccine Drugs 0.000 title claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 63
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 63
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 claims abstract description 47
- 239000013598 vector Substances 0.000 claims abstract description 43
- 239000012528 membrane Substances 0.000 claims abstract description 39
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims abstract description 32
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 32
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 32
- 210000004027 cell Anatomy 0.000 claims abstract description 29
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims abstract description 27
- 108020004414 DNA Proteins 0.000 claims abstract description 15
- 241000700618 Vaccinia virus Species 0.000 claims abstract description 11
- 230000004927 fusion Effects 0.000 claims abstract description 7
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 5
- 230000001580 bacterial effect Effects 0.000 claims abstract description 5
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 24
- 208000005647 Mumps Diseases 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 208000010805 mumps infectious disease Diseases 0.000 claims description 14
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 11
- 208000007089 vaccinia Diseases 0.000 claims description 11
- 238000012546 transfer Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 7
- 102000005396 glutamine synthetase Human genes 0.000 claims description 7
- 108020002326 glutamine synthetase Proteins 0.000 claims description 7
- 230000002480 immunoprotective effect Effects 0.000 claims description 4
- 238000010561 standard procedure Methods 0.000 claims description 3
- 230000001131 transforming effect Effects 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 description 52
- 210000004379 membrane Anatomy 0.000 description 28
- 239000012634 fragment Substances 0.000 description 27
- 239000002299 complementary DNA Substances 0.000 description 26
- 125000000539 amino acid group Chemical group 0.000 description 19
- 108020004705 Codon Proteins 0.000 description 12
- 239000000047 product Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 241000699800 Cricetinae Species 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 101100456896 Drosophila melanogaster metl gene Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000011553 hamster model Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101000914035 Homo sapiens Pre-mRNA-splicing regulator WTAP Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 102100026431 Pre-mRNA-splicing regulator WTAP Human genes 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 125000005555 sulfoximide group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000008478 viral entry into host cell Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the cDNA module (1701 bp) encoding the FS + a + protein was recovered by cleavage with enzymes S al and Ahai ⁇ and introduced into the S al site of the vaccinia transfer vector pULB5213, which is a derived of the standard vaccinia vector pSCl 1 (Chakrabati ej aL 1985, Molecular and Cellular Biology 5, 3403-3409).
- the resutling plasmid, pNIV3205 is illustrated in Fig. IB.
- This cDNA was then amplified by PCR with two sets of primers to generate a first double stranded cDNA fragment corresponding to bases 79 to 629 of the HNmRNA (primers pHN-13 and EcoHNMl) and a second one spanning bases 603 to 1005 (primers EcoHNM2 and pH982).
- the s+FHNa- protein has been detected in d e spent culture medium by immunoprecipitation using a rabbit polyclonal antibody raised against die purified mumps virion; it appeared as a 84 KDa monomer.
- VV3205 F protein 80 44.4% (4 surv. 9 challenged)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne de l'ADN recombiné codant un antigène du virus ourlien choisi dans le groupe contenant: (a) la protéine de fusion pleine longeur (F) complétée par un (des) peptide(s) de signal et le domaine d'ancrage membranaire (a) (désigné ici par Fs+a+); la protéine de fixation pleine longueur ou l'hémagglutinine-neuraminidase (HN); la protéine de nucléocapside pleine longueur (NP); (b) la protéine de fusion tronquée exempte de domaine d'ancrage membranaire (désignée ici par Fs+a-); (c) une protéine hybride dérivée par fusion des protéines F, HN et/ou NP ou des parties de celles-ci. L'invention porte également sur des vecteurs comprenant l'ADN selon l'invention ainsi qu'un hôte tel que le virus de la vaccine, une cellule mammifère ou une cellule bactérienne transformée ou transfectée avec le vecteur, et sur les protéines exprimées par les hôtes.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94915539A EP0695358A1 (fr) | 1993-04-30 | 1994-04-26 | Antigenes recombines du virus ourlien et leur utilisation dans les vaccins |
| KR1019950704819A KR960702000A (ko) | 1993-04-30 | 1994-04-26 | 귀밑샘염 바이러스로부터의 재조합 항원 및 백신에서의 이것의 사용방법(recombinant antigens from mumps virus and their use in vaccines) |
| AU69648/94A AU6964894A (en) | 1993-04-30 | 1994-04-26 | Recombinant antigens from mumps virus and their use in vaccines |
| JP6523863A JPH08512199A (ja) | 1993-04-30 | 1994-04-26 | ムンプスウイルス由来の組換え抗原およびワクチンにおける使用 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939308963A GB9308963D0 (en) | 1993-04-30 | 1993-04-30 | Novel compounds |
| GB9308963.9 | 1993-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1994025600A1 true WO1994025600A1 (fr) | 1994-11-10 |
Family
ID=10734747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1994/001297 WO1994025600A1 (fr) | 1993-04-30 | 1994-04-26 | Antigenes recombines du virus ourlien et leur utilisation dans les vaccins |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0695358A1 (fr) |
| JP (1) | JPH08512199A (fr) |
| KR (1) | KR960702000A (fr) |
| CN (1) | CN1126492A (fr) |
| AU (1) | AU6964894A (fr) |
| CA (1) | CA2161645A1 (fr) |
| GB (1) | GB9308963D0 (fr) |
| WO (1) | WO1994025600A1 (fr) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996004382A2 (fr) * | 1994-07-29 | 1996-02-15 | Chiron Corporation | Proteines virales secretees utiles pour les vaccins et les diagnostics |
| WO1998040492A1 (fr) * | 1997-03-11 | 1998-09-17 | Cambridge Genetics Limited | Compositions et methodes d'elimination de cellules indesirables |
| WO1998052603A2 (fr) * | 1997-05-23 | 1998-11-26 | Schweiz. Serum- & Impfinstitut Bern | Vaccin comprenant de l'adn a enveloppe du virus de la grippe |
| WO2000018929A2 (fr) * | 1998-09-25 | 2000-04-06 | Smithkline Beecham Biologicals S.A. | Nouveaux composés |
| CN1843507B (zh) * | 2006-02-14 | 2010-04-21 | 中国医学科学院医学生物学研究所 | 一种人用腮腺炎病毒组份疫苗及其制备方法和应用 |
| WO2021119497A1 (fr) * | 2019-12-11 | 2021-06-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogènes des virus des oreillons et de la rougeole et utilisation |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106290862B (zh) * | 2016-08-05 | 2017-10-31 | 北京市华信行生物科技有限公司 | 腮腺炎病毒hn抗原及其在检测抗腮腺炎病毒抗体中的用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989011534A1 (fr) * | 1988-05-24 | 1989-11-30 | Board Of Regents, The University Of Texas System | Hemagglutinine-neuraminidase du virus des oreillons |
-
1993
- 1993-04-30 GB GB939308963A patent/GB9308963D0/en active Pending
-
1994
- 1994-04-26 CA CA002161645A patent/CA2161645A1/fr not_active Abandoned
- 1994-04-26 JP JP6523863A patent/JPH08512199A/ja active Pending
- 1994-04-26 EP EP94915539A patent/EP0695358A1/fr not_active Withdrawn
- 1994-04-26 KR KR1019950704819A patent/KR960702000A/ko not_active Application Discontinuation
- 1994-04-26 AU AU69648/94A patent/AU6964894A/en not_active Abandoned
- 1994-04-26 WO PCT/EP1994/001297 patent/WO1994025600A1/fr not_active Application Discontinuation
- 1994-04-26 CN CN94192620.6A patent/CN1126492A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989011534A1 (fr) * | 1988-05-24 | 1989-11-30 | Board Of Regents, The University Of Texas System | Hemagglutinine-neuraminidase du virus des oreillons |
Non-Patent Citations (1)
| Title |
|---|
| KYOSHI TANABAYASHI ET AL.: "Expression of Mumps virus glycoproteins in mammalian cells from cloned cDNAs: Both F and HN proteins are required for cell fusion", VIROLOGY, vol. 187, no. 2, April 1992 (1992-04-01), pages 801 - 804 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100064A (en) * | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
| WO1996004382A2 (fr) * | 1994-07-29 | 1996-02-15 | Chiron Corporation | Proteines virales secretees utiles pour les vaccins et les diagnostics |
| WO1996004382A3 (fr) * | 1994-07-29 | 1996-03-21 | Chiron Corp | Proteines virales secretees utiles pour les vaccins et les diagnostics |
| WO1998040492A1 (fr) * | 1997-03-11 | 1998-09-17 | Cambridge Genetics Limited | Compositions et methodes d'elimination de cellules indesirables |
| US7846429B2 (en) | 1997-03-11 | 2010-12-07 | Mayo Foundation For Medical Education And Research | Compositions and methods for elimination of unwanted cells |
| WO1998052603A2 (fr) * | 1997-05-23 | 1998-11-26 | Schweiz. Serum- & Impfinstitut Bern | Vaccin comprenant de l'adn a enveloppe du virus de la grippe |
| WO1998052603A3 (fr) * | 1997-05-23 | 1999-05-14 | Schweiz Serum & Impfinst | Vaccin comprenant de l'adn a enveloppe du virus de la grippe |
| WO2000018929A2 (fr) * | 1998-09-25 | 2000-04-06 | Smithkline Beecham Biologicals S.A. | Nouveaux composés |
| WO2000018929A3 (fr) * | 1998-09-25 | 2000-11-09 | Smithkline Beecham Biolog | Nouveaux composés |
| CN1843507B (zh) * | 2006-02-14 | 2010-04-21 | 中国医学科学院医学生物学研究所 | 一种人用腮腺炎病毒组份疫苗及其制备方法和应用 |
| WO2021119497A1 (fr) * | 2019-12-11 | 2021-06-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogènes des virus des oreillons et de la rougeole et utilisation |
Also Published As
| Publication number | Publication date |
|---|---|
| KR960702000A (ko) | 1996-03-28 |
| CN1126492A (zh) | 1996-07-10 |
| CA2161645A1 (fr) | 1994-11-10 |
| JPH08512199A (ja) | 1996-12-24 |
| AU6964894A (en) | 1994-11-21 |
| EP0695358A1 (fr) | 1996-02-07 |
| GB9308963D0 (en) | 1993-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2031164C (fr) | Herpesvirus recombinant de dindons et vaccins de vecteur vivant qui en sont derives | |
| US5242829A (en) | Recombinant pseudorabies virus | |
| KR970011149B1 (ko) | 재조합 아비폭스 바이러스 | |
| KR0166585B1 (ko) | 앵커-결여 vzv 당단백질, 이를 제조하는 방법 및 이의 면역보호적 용도 | |
| US5021347A (en) | Recombinant vaccinia virus expressing E-protein of Japanese encephalitis virus | |
| WO1994017810A1 (fr) | Vaccin recombine contre le cytomegalovirus | |
| US4810492A (en) | Flavivirus antigen | |
| EP0510773B1 (fr) | Vaccin de sous-unités contre le coronavirus canin | |
| JPH08173171A (ja) | ヒト呼吸器系ウイルス用ワクチン | |
| Kit et al. | Modified-live infectious bovine rhinotracheitis virus vaccine expressing monomer and dimer forms of foot-and-mouth disease capsid protein epitopes on surface of hybrid virus particles | |
| EP0538341B1 (fr) | Vaccin a base de glycoproteine de vhe-4 (virus d'herpes equin-4) | |
| CA2156423A1 (fr) | Virus recombinants de molluscum contagiosum et leurs utilisations | |
| EP0695358A1 (fr) | Antigenes recombines du virus ourlien et leur utilisation dans les vaccins | |
| Ray et al. | Expression of the fusion glycoprotein of human parainfluenza type 3 virus in insect cells by a recombinant baculovirus and analysis of its immunogenic property | |
| EP0423869B1 (fr) | Vaccin contre le virus de la bronchite infectieuse (IBV) | |
| EP0606452A1 (fr) | Vaccins vecteurs d'herpesvirus felin recombine | |
| WO1995009249A1 (fr) | Vaccination per os des mammiferes | |
| US5486473A (en) | A DNA coding for a Flavivirus antigen | |
| US5674735A (en) | DNA encoding the EHV-4 gH or gC glycoprotein | |
| AU634512B2 (en) | Expression of the plasmodium circumsporozoite protein in insect cells | |
| SONDERMEIJER et al. | Sommaire du brevet 2028045 | |
| DK175980B1 (da) | Recombinante vacciniavira og anvendelsen af samme | |
| SONDERMEIJER et al. | Patent 2028045 Summary | |
| NZ259362A (en) | Varicella zoster virus immediate early protein 175 (vzv iep 175) and derivatives, its production and use | |
| WO1994000587A2 (fr) | Herpesvirus-4 equin attenue utilise comme vaccin vivant ou vecteur recombine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 94192620.6 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR NZ SI US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1994915539 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 291162 Country of ref document: NZ |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2161645 Country of ref document: CA |
|
| WWP | Wipo information: published in national office |
Ref document number: 1994915539 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 1996 535242 Country of ref document: US Date of ref document: 19960318 Kind code of ref document: A |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1994915539 Country of ref document: EP |